The first dosing of Folotyn in China by CASI Pharmaceuticals is a critical step towards the company's expansion in the Chinese market, which could lead to increased revenues and market share. This development is likely to be viewed positively by investors, potentially leading to a short-term uptick in CASI's stock price.